SHINJIRO SAKAMOTO

Last Updated :2022/12/02

Affiliations, Positions
Hiroshima University Hospital, Assistant Professor
E-mail
s-sakamotohiroshima-u.ac.jp
Self-introduction
I am familiar with various respiratory diseases, especially studies on lung cancer / cancer immunity

Basic Information

Academic Degrees

  • Hiroshima University

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Respiratory organ internal medicine

Research Keywords

  • Respiratory Medicine

Affiliated Academic Societies

  • The Japanese society of internal medicine
  • The Japanese respiratory society

Educational Activity

Course in Charge

  1. 2022, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2022, Undergraduate Education, Intensive, Symptomatology, Diagnosis and Treatment
  3. 2022, Undergraduate Education, Intensive, Practice of Medicine I
  4. 2022, Undergraduate Education, Intensive, Practice of Medicine II

Research Activities

Academic Papers

  1. ★, Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele., Cancer Sci., 108(4), 598-603
  2. ★, Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer, CLINICAL LUNG CANCER, 18(6), E385-E394, NOV 2017
  3. AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma, ONCOTARGET, 8(55), 94382-94392, NOV 7 2017
  4. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma, LUNG CANCER, 119, 21-24, MAY 2018
  5. ★, Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele, CANCER SCIENCE, 106(10), 1257-1263, 2015
  6. ★, Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination, HUMAN VACCINES & IMMUNOTHERAPEUTICS, 11(12), 2784-2789, 2015
  7. ★, Prospect and progress of personalized peptide vaccinations for advanced cancers, EXPERT OPINION ON BIOLOGICAL THERAPY, 16(5), 689-698, 2016
  8. Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer, EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2016
  9. Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site, CANCER IMMUNOLOGY IMMUNOTHERAPY, 65(10), 1223-1231, 2016
  10. A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer, CANCER SCIENCE, 108(5), 838-845, 2017
  11. Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens, INTERNATIONAL JOURNAL OF ONCOLOGY, 46(1), 55-62, 2015
  12. PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer, CANCER SCIENCE, 105(10), 1229-1235, 2014
  13. Single nucleotide polymorphisms of the haptoglobin gene in non-small cell lung cancer treated with personalized peptide vaccination, ONCOLOGY LETTERS, 13(2), 993-999, 2017
  14. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study, IN VIVO, 32(5), 1155-1160, 2018
  15. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study, IN VIVO, 32(5), 1155-1160, SEP-OCT 2018
  16. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study, MOLECULAR AND CLINICAL ONCOLOGY, 9(5), 539-544, 201811
  17. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody A retrospective cohort study, MEDICINE, 97(49), 201812
  18. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1, CANCER LETTERS, 442, 31-39, 2019
  19. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery, MEDICINE, 98(5), 201902
  20. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma A case report, MEDICINE, 98(12), 201903
  21. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts, JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 23(4), 2984-2994, 201904
  22. Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients, INTERNAL MEDICINE, 58(7), 915-920, 2019
  23. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress, FREE RADICAL BIOLOGY AND MEDICINE, 136, 52-59, 20190520
  24. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia, RESPIRATORY MEDICINE, 152, 44-50, 201906
  25. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, RESPIRATORY INVESTIGATION, 57(5), 451-459, 201909
  26. AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma, ONCOTARGET, 8(55), 94382-94392, 2017
  27. Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer, CLINICAL LUNG CANCER, 18(6), E385-E394, 2017
  28. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma, LUNG CANCER, 119, 21-24, 2018
  29. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study, MOLECULAR AND CLINICAL ONCOLOGY, 9(5), 539-544, 2018
  30. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody A retrospective cohort study, MEDICINE, 97(49), 2018
  31. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1, CANCER LETTERS, 442, 31-39, 2019
  32. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery, MEDICINE, 98(5), 2019
  33. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma A case report, MEDICINE, 98(12), 2019
  34. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts, JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 23(4), 2984-2994, 2019
  35. Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients, INTERNAL MEDICINE, 58(7), 915-920, 2019
  36. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress, FREE RADICAL BIOLOGY AND MEDICINE, 136, 52-59, 2019
  37. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia, RESPIRATORY MEDICINE, 152, 44-50, 2019
  38. Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, RESPIROLOGY, 2019
  39. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, RESPIRATORY INVESTIGATION, 57(5), 451-459, 2019
  40. Immunological evaluation of peptide vaccination for cancer patients with the HLA-A11(+) or-A33(+) allele, CANCER SCIENCE, 108(4), 598-603, 2017
  41. C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis, RESPIRATION, 98(3), 212-220, 201909
  42. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer, ANTICANCER RESEARCH, 39(10), 5725-5731, 201910
  43. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25(1), 74-81, 202001
  44. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25(1), 74-81, 202001
  45. Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer, JOURNAL OF THORACIC DISEASE, 12(3), 1079-1084, 202003
  46. Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, RESPIROLOGY, 25(3), 275-280, 202003
  47. Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients, INTERNATIONAL JOURNAL OF ONCOLOGY, 56(6), 1479-1479, 202006
  48. Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, RESPIRATORY RESEARCH, 21(1), 20200611